Literature DB >> 12801442

Optimal medical management of angina.

Brian Noronha1, Edward Duncan, Jonathan A Byrne.   

Abstract

Coronary artery disease remains one of the principal causes of disability worldwide. Its most common manifestation is angina pectoris. Angina occurs due to an imbalance between myocardial oxygen demand and supply; it is classically precipitated by physical activity, emotion, eating, or cold weather. It is defined as stable when its frequency, severity, duration, time of appearance, and precipitating factors remain unchanged for 60 days. Treatment of patients with stable angina targets a number of factors that underlie its pathophysiology: aspirin as an antiplatelet agent, b-blockade to reduce myocardial oxygen demand, and additional antianginal drugs when symptoms are incompletely controlled by b-blockers alone. Furthermore, aggressive treatment of risk factors for the development of coronary artery disease confers a significant mortality benefit. Unstable angina is defined as symptoms developing at rest, on minimal exertion, and of increasing severity, duration, or frequency. It is associated with significant mortality; consequently, early assessment and intervention is essential to prevent worsening ischemia. Treatment includes close in-patient monitoring, administration of antiplatelet and antithrombotic drugs, and a combination of b-blockers, calcium antagonists, and intravenous nitrates where appropriate. Coronary revascularization should be considered in high-risk patients, and when conservative management strategies fail.

Entities:  

Mesh:

Year:  2003        PMID: 12801442     DOI: 10.1007/s11886-003-0060-x

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  48 in total

Review 1.  Detailed diagnoses and procedures, National Hospital Discharge Survey, 1996.

Authors:  E J Graves; L J Kozak
Journal:  Vital Health Stat 13       Date:  1998-09

2.  Unstable angina. A classification.

Authors:  E Braunwald
Journal:  Circulation       Date:  1989-08       Impact factor: 29.690

3.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

4.  Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).

Authors: 
Journal:  Eur Heart J       Date:  1999-11       Impact factor: 29.983

5.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

6.  Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial.

Authors: 
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

7.  Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death.

Authors:  M J Davies; A C Thomas; P A Knapman; J R Hangartner
Journal:  Circulation       Date:  1986-03       Impact factor: 29.690

8.  The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life.

Authors:  S Wassertheil-Smoller; A Oberman; M D Blaufox; B Davis; H Langford
Journal:  Am J Hypertens       Date:  1992-01       Impact factor: 2.689

9.  Risk stratification in unstable angina. Prospective validation of the Braunwald classification.

Authors:  J E Calvin; L W Klein; B J VandenBerg; P Meyer; J V Condon; R J Snell; L M Ramirez-Morgen; J E Parrillo
Journal:  JAMA       Date:  1995-01-11       Impact factor: 56.272

10.  Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1986-07-12       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.